By admin 
The landscape of pediatric oncology is witnessing a significant shift as researchers move beyond traditional cytotoxic treatments toward the precision of cellular immunotherapy. Dr. Hunter Jonus, a PhD researcher and CureSearch Young Investigator within the Department of Pediatrics at Emory University, is currently at the forefront of this evolution. Her work focuses on high-risk neuroblastoma, a devastating form of childhood cancer that has long challenged the medical community due to its aggressive nature and high rate of recurrence. By leveraging the unique properties of gamma delta (γδ) T cells, Dr. Jonus and her team are developing a novel therapeutic framework that aims to increase survival rates while minimizing the long-term toxicities associated with conventional chemotherapy and radiation.
The Clinical Challenge of High-Risk Neuroblastoma
Neuroblastoma is the most common extracranial solid tumor diagnosed in infants and young children, accounting for approximately 7% to 10% of all pediatric cancers. It originates in the primordial crest cells of the sympathetic nervous system, typically manifesting in the adrenal glands, neck, chest, or spinal cord. While some forms of neuroblastoma are highly treatable and may even undergo spontaneous regression, nearly half of all patients present with high-risk disease at the time of diagnosis.
High-risk neuroblastoma is characterized by extensive metastasis or specific genetic markers, such as MYCN gene amplification. For these children, the prognosis remains sobering. Despite an intensive multi-modal treatment regimen involving high-dose chemotherapy, surgical resection, stem cell transplantation, and radiation, the five-year survival rate hovers around 50%. The situation becomes even more dire if the cancer relapses. For children with recurrent high-risk neuroblastoma, the overall survival rate plummets to less than 20%.
Furthermore, the "cure" often comes at a steep price. Survivors of high-risk neuroblastoma frequently face a lifetime of chronic health issues resulting from the intensity of their treatment. These include permanent hearing loss, cardiovascular complications, infertility, and a significantly heightened risk of developing secondary malignancies later in life. The urgent need for more targeted, less toxic therapies is what drives the current research led by Dr. Jonus at Emory University.
The Science of Gamma Delta T Cells
The core of Dr. Jonus’s research lies in the utilization of gamma delta (γδ) T cells, a specialized subset of T lymphocytes that bridge the gap between innate and adaptive immunity. Unlike the more common alpha beta (αβ) T cells, which require the recognition of specific antigens presented by Major Histocompatibility Complex (MHC) molecules, γδ T cells can recognize and kill tumor cells independently of MHC.
This distinction is critical for two reasons. First, many tumors, including neuroblastoma, "hide" from the immune system by downregulating their MHC expression. Because γδ T cells do not rely on MHC, they can detect these "invisible" cancer cells. Second, because they are not MHC-restricted, γδ T cells carry a significantly lower risk of causing Graft-versus-Host Disease (GvHD). This allows for the possibility of "off-the-shelf" therapies where cells are harvested from healthy donors, expanded in a laboratory setting, and administered to multiple patients without the need for perfect genetic matching.
Dr. Jonus’s methodology involves extracting these cells from healthy donors and utilizing ex vivo expansion techniques to grow them into a potent therapeutic army. Once infused into the patient, these cells are designed to seek out and destroy neuroblastoma cells while sparing healthy tissue, potentially offering a safer profile than systemic chemotherapy.
Chronology of Research and Clinical Implementation
The transition from laboratory discovery to clinical application is a rigorous process that spans several years. Dr. Jonus’s work has followed a structured timeline of development:
- Pre-clinical Validation: Extensive laboratory studies were conducted to determine the optimal conditions for expanding γδ T cells and to verify their cytotoxicity against various neuroblastoma cell lines.
- Selection as CureSearch Young Investigator: Recognizing the potential of her work, CureSearch for Children’s Cancer awarded Dr. Jonus the Young Investigator grant. This funding is specifically designed to support early-career scientists who are bridging the gap between basic science and clinical trials.
- Integration with Chemoimmunotherapy: Dr. Jonus began exploring the synergistic effects of combining γδ T cells with existing chemoimmunotherapy protocols. This led to the hypothesis that chemotherapy could "prime" the tumor environment, making it more susceptible to the subsequent infusion of T cells.
- First-in-Child Clinical Trial: This research has culminated in a landmark first-in-child clinical trial conducted at Children’s Healthcare of Atlanta (CHOA). The trial marks one of the first times that healthy donor-derived γδ T cells have been combined with standard-of-care chemoimmunotherapy for pediatric neuroblastoma.
Advancing Efficacy through Genetic Engineering
While the current clinical trial represents a major milestone, Dr. Jonus is already looking toward the next generation of cellular therapy. A primary challenge in treating solid tumors with immunotherapy is the "hostile" tumor microenvironment, which can suppress immune cell function and limit the longevity of the treatment.
To overcome these barriers, Dr. Jonus is pioneering the use of Chimeric Antigen Receptors (CARs) specifically engineered for γδ T cells. By equipping these cells with CARs, researchers can program them to recognize specific proteins found on the surface of neuroblastoma cells, such as GD2. This increases the precision of the attack.
Additionally, her future research focus includes:
- Cytokine Secretion: Engineering γδ T cells to secrete specific cytokines (signaling proteins) that help the cells survive longer within the patient’s body and recruit other immune cells to the tumor site.
- Immune Checkpoint Blockade: Integrating therapies that block "checkpoints"—the brakes that tumors put on the immune system—to ensure that the γδ T cells remain active and functional until the malignancy is eradicated.
Supporting Data and the Landscape of Pediatric Cancer Funding
The importance of Dr. Jonus’s work is underscored by the broader statistics regarding pediatric cancer research funding. Historically, pediatric cancer has received a disproportionately small share of federal research funding compared to adult cancers. According to the National Cancer Institute (NCI), only about 4% of the federal budget for cancer research is dedicated specifically to childhood cancers.
This funding gap often results in what researchers call the "Valley of Death," where promising laboratory discoveries fail to reach clinical trials due to a lack of financial support. Organizations like CureSearch play a vital role in filling this void. By funding Young Investigators like Dr. Jonus, these organizations ensure that innovative ideas are not lost and that the next generation of oncology leaders has the resources necessary to bring new treatments to the bedside.
The data from initial studies on γδ T cell therapy in other malignancies have shown a manageable safety profile, with fewer cytokine release syndrome (CRS) events compared to traditional CAR-T therapies. This data provides a strong foundation for the ongoing trials in neuroblastoma, suggesting that this approach could eventually become a standard component of high-risk treatment protocols.
Institutional and Professional Reactions
The selection of Dr. Jonus as a CureSearch Young Investigator has been met with enthusiasm within the academic and medical communities. Emory University’s Department of Pediatrics has long been a hub for pediatric innovation, and the partnership with Children’s Healthcare of Atlanta provides a unique environment where bench-to-bedside research can flourish.
In a statement reflecting on her selection and the future of her research, Dr. Jonus expressed a profound sense of urgency and optimism. “I am ecstatic to be selected as a CureSearch Young Investigator and for the opportunity to conduct this meaningful research with significant potential to impact patients’ lives,” she stated. “I am hopeful for the future of γδ T cell immunotherapy and its possibility to overcome barriers in the field of adoptive cell therapy so that more patients will be able to receive this powerful treatment approach.”
Colleagues in the field of pediatric hematology and oncology have noted that the "off-the-shelf" potential of Dr. Jonus’s work is particularly promising. If successful, it could drastically reduce the time and cost associated with personalized cell therapies, which currently require harvesting and modifying a patient’s own cells—a process that is often difficult in children who have already undergone heavy chemotherapy.
Broader Implications for Pediatric Oncology
The implications of Dr. Jonus’s research extend far beyond neuroblastoma. The success of γδ T cell platforms could provide a blueprint for treating other "cold" pediatric solid tumors—cancers that typically do not respond well to traditional immunotherapy—such as osteosarcoma or Ewing sarcoma.
By shifting the focus toward the innate-like properties of γδ T cells, the medical community is moving closer to a reality where "universal" donor cells can be used to treat a variety of pediatric malignancies. This would not only improve survival rates but also democratize access to advanced therapies, making them available to a wider range of patients across different clinical settings.
As the clinical trial at Children’s Healthcare of Atlanta progresses, the oncology community will be watching closely. The data gathered will be instrumental in refining how cellular therapies are integrated into the complex treatment landscape of high-risk neuroblastoma. For the families of children diagnosed with this aggressive disease, Dr. Jonus’s work represents more than just scientific progress; it represents a tangible hope for a future where a diagnosis of high-risk neuroblastoma is no longer a life-threatening crisis, but a manageable and curable condition.
